Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. Show more

Location: 910 Clopper Road, Gaithersburg, MD, 20878, United States | Website: https://altimmune.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

335.8M

52 Wk Range

$2.90 - $11.16

Previous Close

$4.40

Open

$4.32

Volume

4,159,229

Day Range

$4.10 - $4.35

Enterprise Value

165.6M

Cash

149.8M

Avg Qtr Burn

-20.08M

Insider Ownership

0.76%

Institutional Own.

47.85%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Metabolic dysfunction-associated steatohepatitis (MASH)

Phase 2b

Data readout

Phase 2

Data readout

Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Alcohol-Associated Liver Disease

Phase 2

Data readout

Phase 2

Update

NasoShield (Vaccine) Details
Anthrax, Bacterial infection

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

HepTCell Details
Chronic hepatitis B

Failed

Discontinued